

Consolidated Financial Results for the Fiscal Year Ending March 31, 2015

1. Outline of Consolidated Financial Results	P.1
2. Highlights of Business Performance	P.2
3. Consolidated Financial Results	P.3
4. Main Product Sales Update	P.4
5. Actual and Forecast of Main Subsidiary Companies	P.5
6. R&D Expenses, Capex & Depreciation	P.6
7. Main R&D Activities	P.7~8
【reference】	
8. Segment information	P.10
9. P&L Summary	P.11~12
10. BS Summary	P.13
11. Financial summary	P.14
12. KYORIN Pharmaceutical result	P.15~18

May 13, 2015

KYORIN Holdings, Inc.

These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.



Outline of Consolidated Financial Results for Fiscal 2014

(¥ million)	FY2011	FY2012	FY2013	FY2014	change	FY2015 (forecast)	change
Net sales	103,232	107,031	111,400	113,121	+1.5%	120,200	+6.3%
Operating income	14,464	17,948	17,607	14,737	-16.3%	16,000	+8.6%
Ordinary income	15,275	18,676	18,281	15,490	-15.3%	16,300	+5.2%
Net income	9,231	12,422	12,025	12,064	+0.3%	11,500	-4.7%
Net income per share (yen)	123.54	166.25	160.95	161.63	+0.3%	155.51	-4.7%
Total assets	145,673	154,968	169,378	183,383	+8.3%	—	—
Total equity	118,201	129,099	137,821	148,600	+7.8%	—	—

Consolidated Business Results for Fiscal 2014

【Net sales】 Overall net sales increased 1.5% year on year to ¥113.1 billion. Sales growth was driven by year on year increased in a new product Flutiform and main product, generic drug sales, despite lower sales in the ethical drug due to drug price revision and .


【Net income】 Gross profit declined ¥1.8 billion year on year due to a rise in the cost ratio, mainly reflecting the revision in the National Health Insurance drug pricing and changes in the product sales mix in the Ethical drugs Business. Operating income amounted to ¥14.7 billion (a decrease of 16.3% year on year) due to increase of R&D expenses. Net income increased at ¥12.1 billion (up 0.3% year on year) due to posting extraordinary income ¥4.5 billion and extraordinary loss ¥2.4 billion.

Consolidated Business Results Forecast for Fiscal 2015

【 Net Sales and Income 】We expect sales to grow due to new product Flutiform and generic drugs sales and gross profit rose due to the increase of Net sales. As a result, we expect net sales to increase 6.3% year on year to ¥120.2bn, operating income to increase 8.6% to ¥16.0bn, and net income to decrease 4.7% to ¥115.0bn.

Highlights of Business Performance

(Units: ¥ billion)



➤ **Net Sales increased ¥1.7billion year on year.**
 • increase of Flutiform, Kipres sales
 • decrease of long listed drugs sales
 • increase of generic drugs sales

➤ **Cost of Sales increased ¥3.6 billion.**
(Cost of sales ratio increased 2.6%)
 • Drug price revisions
 • Product sales mix (increase of generic drugs sales)

■ **Gross Profit decreased ¥1.9billion year on year**

➤ **SG&A expenses increased ¥1.1billion year on year**
 • R&D expenses increased ¥2.1billion
 • SG&A (excluding R&D) decreased ¥1.1billion

■ **Operating Income decreased ¥2.9billion year on year**

Consolidated Financial Results

(unit : ¥ billion)

	FY2013	FY2014	change
Net Sales (total)	111.4	113.1	+1.7
Ethical drugs Business	109.7	111.8	+2.1
◆Sales of new ethical drugs	93.5	92.1	-1.4
●Japan	91.7	91.1	-0.6
●Overseas	1.8	1.0	-0.8
◆Generic drugs	12.0	15.5	+3.5
◆Over-the-counter drugs	4.2	4.2	0
Healthcare (Skin care) Business	1.7	1.3	-0.4

Operating Income	17.6	14.7	-2.9
Ordinary Income	18.3	15.5	-2.8
Net Income	12.0	12.1	+0.1

■Dividend per share(interim dividend ¥20.0) **¥52.0**

Dividend ratio 32.2%

		(change actual)	(change forecast)
■Net Sales	¥113.1	(+ 1.7)	(+ 1.4)
◆Ethical drugs business	¥111.8	(+ 2.1)	(+ 1.8)
●Sales of new ethical drugs	¥91.1	(- 0.6)	(+ 1.4)
FY13			
FY14			
• Kipres	40.2 ⇒ 41.2	(+1.0)	(+1.0)
• Mucodyne	18.4 ⇒ 14.0	(-4.4)	(+0.2)
• Pentasa	18.6 ⇒ 17.2	(-1.4)	(+0.5)
• Uritos	8.1 ⇒ 7.3	(-0.8)	(-0.2)
• Flutiform	0.6 ⇒ 3.6	(+3.0)	(-0.3)
●Sales of new ethical drugs in Overseas	¥1.0	(- 0.8)	(0)
• Gatifloxacin	1.5 ⇒ 0.6	(- 0.9)	(+0.1)
●Sales of Generic drugs	¥15.5	(+ 3.5)	(+ 0.5)
Contract manufacturing's sales and Health insurance pharmacy market's sales increased			
●Sales of Over-the-counter drugs	¥4.2	(0)	(0)
◆Healthcare (Skin care) Business	¥1.3	(- 0.4)	(-0.3)
■Operating Income	¥14.7	(- 2.9)	(+ 0.9)
◆Operating Income margin decreased 2.8 percentage points to 13.0%			
●Cost of Sales Ratio : 38.6%⇒41.2% increased 2.6 percentage points			
• Drug price revisions (in the 6%range for KYORIN Pharmaceutical).			
• Product sales mix (increase of generic drugs sales)			
●R&D Ratio : 10.2%⇒11.9% increased 1.7 percentage points			
* ¥11.4bln⇒¥13.5bln (+¥2.1bln) upfront payment of KRP-114V,progress of pipeline			
●SG&A Ratio : 35.4%⇒33.8% decreased 1.6 percentage			
* ¥39.4bln⇒¥38.3bln (-¥1.1bln) decrease of sales costs			
■Net Income	¥12.1	(+ 0.1)	(+ 0.5)

•extraordinary income : 4.5 billion yen for the transfer of the land and building of the former head office building

•extraordinary losses : 1.7 billion yen for the use of the vacant lot of the Pharmaceutical Discovery Research Laboratories

Main Product Sales Update

(Units: ¥ billion)

		FY2010	FY2011	FY2012	FY2013	FY2014		FY2015 (forecast)
						actual	Change(%)	
Sales of new ethical drugs (Japan)	Kipres (LT receptor antagonist)	34.5	36.8	39.6	40.2	41.2	+2.7	41.8
	Mucodyne (Mucoregulant)	21.3	21.5	19.1	18.4	14.0	-23.7	11.8
	Pentasa (Ulcerative colitis and Crohn's disease treatment)	19.4	18.0	17.6	18.6	17.2	-7.4	17.1
	Uritos (Kyorin) (Overactive bladder)	5.5	6.3	7.5	8.1	7.3	-9.5	7.9
	Ketas (For bronchial asthma and cerebrovasculas disorders)	4.0	3.4	3.0	2.8	2.1	-25.5	1.7
	Flutiform (Anti-asthmatic)	—	—	—	0.6	3.6	+518.9	10.3

Sales of new ethical drugs (over seas)	Gatifloxacin (Bulk · Royalty)	2.2	1.7	1.6	1.5	0.6	-57.8	0.4
--	---	-----	-----	-----	-----	-----	-------	-----

Over-the-counter drugs	Milton (Disinfectant)	1.9	1.9	2.0	2.1	2.0	-3.2	2.0
------------------------	---------------------------------	-----	-----	-----	-----	-----	------	-----

Main Subsidiary Companies

(Units: ¥ billion)

KYORIN pharmaceutical	FY2013	FY2014
Sales	97.7	98.5
Operating Income	15.4	12.2
Net Income	10.8	10.4

FY2015(forecast)
105.3
13.3
10.0

KYORIN Rimedio	FY2013	FY2014
Sales	12.4	16.4
Operating Income	1.0	2.1
Net Income	0.6	1.5

FY2015(forecast)
18.5
2.3
1.6

Dr. Program	FY2013	FY2014
Sales	1.8	1.4
Operating Income	0.2	0.0
Net Income	0.2	0.0

FY2015(forecast)
1.6
0.0
0.0

R&D Expenses, Capex & Depreciation

(Units: ¥ million)

	FY2010	FY2011	FY2012	FY2013	FY2014		FY2015 (forecast)
					actual	change	
R&D expenses	12,495	13,964	11,059	11,359	13,514	+19.0%	13,400
Capital expenditure	1,668	1,952	6,576	6,500	2,655	-59.2%	8,700
Depreciation expense	2,458	2,363	2,738	3,153	3,053	-3.2%	3,800

<Capital expenditure (Actual/Forecast)>

(Units: ¥ billion)

	FY2013	FY2014	FY2015 (forecast)
Plant facilities	1.9	1.5	2.9
Equipment for control, sales activities	0.7	0.3	0.8
Equipment for research	3.9	0.8	5.0

Main R&D Activities -1 (May 13, 2015 Release)

Ph III ~ Application submitted

※Changes from the previous announcement(Feb 2 2015)

Stage		Compound/ Code	Therapy area/Action	Origin	Features	Comments
Japan	Overseas					
※Approval (3/2015)	(Europe) AstraZeneca : Launched(9/2012) (US) AstraZeneca : Launched (12/2012)	KRP-AB1102 (Inhaled drug)	Chronic Obstructive Pulmonary Disease (COPD)	Almirall	- New Chemical Entity: Acridinium Bromide - Long Acting Muscarinic Agonist (LAMA) - Twice Daily administration -Onset of Action on the first day Genuair® 1) Designed with a feedback system, which through a 'colored control window' and an audible click helps confirm that the patient has inhaled correctly 2) Counter for remaining doses 3) Safety features such as an anti-double-dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler	License agreement with Almirall (2/2011)
PhIII (13年8月)	(Europe) AstraZeneca : Launched (1/2015) (US) AstraZeneca : PhIII	KRP-AB1102F (Fixed dose combination inhaled drug)	Chronic Obstructive Pulmonary Disease (COPD)	Almirall	Combination of acridinium bromide with the long acting beta agonist formoterol : This combination is aimed at providing higher efficacy than each component alone,as well as the improved convenience of having the two products in the same easy to use inhalation device.This is currently in phase III clinical development.	
PhIII (1/2015)	Ph II clinical trial end Merck & Co.,	KRP-114V	Overactive bladder	Merck & Co.,	KRP-114V is expected to improve urinary frequency through stimulation of the beta 3 receptor in bladder which improves bladder muscle relaxation.	License agreement with Merck & Co., Inc.,(7/2014)
※PhIII (4/2015)		KRP-AM1977X (Oral agent)	New quinolone synthetic antibacterial agent	In-house	①Superior ability to combat drug-resistant gram- positive bacteria (incl. MRSA) ②Outstanding ADME (oral absorption, tissue migration) ③High degree of safety expected since safety hurdles cleared prior to clinical trials	

Main R&D Activities -2 (May 13, 2015 Release)

POC Project (Ph I ~ Ph II)

※Changes from the previous announcement(Feb 2 2015)

Stage		Compound/ Code	Therapy area/Action	Origin	Features	Comments
Japan	Overseas					
Ph II (8/2011)	Ph III Merz	KRP-209	Tinnitus	Merz	KRP-209 (Neramexane) is expected to improve the patients' annoyance and difficulties in their life caused by tinnitus, mainly through its two pharmacological properties: 1) NMDA antagonistic activity and 2) Nicotinic acetylcholine antagonistic activity	License agreement with Merz (11/2009) Merz:Ph I clinical trial of Japanese patients in US completed (3/2010)
Ph II (3/2013)	Ph II (POC) (12/2010) (Novartis)	KRP-203	Transplantation, autoimmune diseases, and IBD	In-house	An immunosuppressant with a novel mechanism called an S1P-agonist. It may have a better safety profile than previous ones as well as an excellent effect under concomitant use with other types of immunomodulator.	License agreement with Novartis (2/2006) New license agreement IBD (11/2010)
Ph II (6/2014)		KRP-AM1977Y (Injection)	New quinolone synthetic antibacterial agent	In-house	①Superior ability to combat drug-resistant gram-positive bacteria (incl. MRSA) ②Outstanding ADME (oral absorption, tissue migration) ③High degree of safety expected since safety hurdles cleared prior to clinical trials	

for reference

Stage	Compound/ Code	Therapy area/Action	Features	Comments
under development by MSD K.K. (Ph III)	Desloratadine	allergic rhinitis, hives, itching resulting from skin diseases (eczema/dermatitis, pruritus cutaneous)	second generation histamine H1-receptor antagonist	Co-Marketing Agreement for Japan with MSD K.K. affiliate (11/2014)

Reference

Segment information

Sales, Profit or Loss of each report segment

(Units: ¥ billion)

	Sales	change	Profit	Change
Net Sales (total)	113.1	+1.7	14.7	-2.9
Ethical drugs business	111.8	+2.1	14.6	-2.4
◆Sales of new ethical drugs	92.1	-1.4		
○Japan	91.1	-0.6		
○Overseas	1.0	-0.8		
◆Generic drugs	15.5	+3.5		
◆Over-the-counter drugs	4.2	0.0		
Healthcare(Skincare) business	1.3	-0.4	0.0	-0.2
Amount of adjustment	-	-	0.2	-0.3

(Note) The Company is applying the Revised Accounting Standard for Disclosures about Segments of an Enterprise and Related Information and the Guidance on the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information. As a result, the reported segments are the Ethical Drugs Business and the Consumer Healthcare Business.

P&L Summary: Consolidated Results – (1)

(Units: ¥ million)

	FY2013		FY2014			
	Actual	% Sales	Actual	% Sales	% Change	Change
Sales	111,400	100.0%	113,121	100.0%	+1.5	+1,721
■ Ethical Drugs business	109,678	98.5%	111,771	98.8%	+1.9	+2,093
◆ Sales of new Ethical Drugs	93,518	83.9%	92,111	81.4%	-1.5	-1,407
○ Japan	91,668	82.3%	91,079	80.5%	-0.6	-589
○ Overseas	1,849	1.7%	1,032	0.9%	-44.2	-817
◆ Generic Drugs	11,987	10.8%	15,477	13.7%	+29.1	+3,490
◆ Over-the-counter Drugs and Others	4,172	3.7%	4,183	3.7%	+0.3	+11
■ Consumer Healthcare Business	1,721	1.5%	1,349	1.2%	-21.6	-372

<Subsidiaries and Equity-method Affiliates>

Consolidated subsidiaries (8) :

KYORIN Pharmaceutical Co., Ltd.
Kyorin USA, Inc.
Kyorin Europe GmbH
ActivX Biosciences, Inc.
KYORIN Rimedio Co., Ltd.
Dr. Program Co., Ltd.
KYORIN Medical Supply Co., Ltd.
KYORIN Pharmaceutical Facilities Co., Ltd

Equity-Method Affiliates: Nippon Rika Co., Ltd.

< Breakdown >

■ Sales	¥ 113,121		change	(+¥1,721)
● Ethical drug sales in Japan	¥91,079		(- ¥589)	
	FY13	FY14	(¥:billion)	
• Kipres	40.2	⇒ 41.2	(+1.0)	
• Mucodine	18.4	⇒ 14.0	(-4.4)	
• Pentasa	18.6	⇒ 17.2	(-1.4)	
• Uritos	8.1	⇒ 7.3	(-0.8)	
• Flutiform	0.6	⇒ 3.6	(+3.0)	
● Ethical drug sales overseas	¥1,032		(- ¥817)	
• Gatifloxacin	1.5	⇒ 0.6	(-0.9)	
● Generic Drugs	¥ 15,477		(+¥3,490)	
* Health insurance pharmacy market's sales and contract manufacturing's sales increased.				
● Over-the-counter Drugs and Others	¥4,183		(+ ¥11)	
● Consumer Healthcare Business	¥1,349		(- ¥372)	
* decrease of Dr.Program's sales				

BS Summary: Consolidated Results

(Units: ¥ million)	FY2013	
	Actual	%total
Current Assets	121,638	71.8%
Cash, deposits	31,017	
Notes and accounts receivable	44,123	
Mk securities	17,965	—
Inventory	21,699	
Other	6,833	
Fixed Assets	47,740	28.2%
Tangible assets	20,841	
Intangible assets	1,198	
Investments	25,700	—
Total Assets	169,378	100.0%

Current Liabilities	28,401	16.8%
Notes payable	11,056	
Other	17,344	—
Non-Current Liabilities	3,155	1.9%
Total Liabilities	31,557	18.6%
Owner's Equity	135,273	79.9%
Other Comprehensive Income	2,548	1.5%
Unrealized holding gain (loss) on securities	3,434	
Foreign currency translation adjustments	12	—
	-898	
Total Equity	137,821	81.4%
Total Liabilities and Equity	169,378	100.0%

FY2014		
Actual	% total	change
129,064	70.4%	+7,426
30,652		
47,007		
17,867	—	—
25,929		
7,607		
54,318	29.6%	+6,578
19,374		
1,184	—	—
33,760		
183,383	100.0%	+14,005

27,773	15.1%	-628
11,259		
16,513	—	—
7,009	3.8%	+3,854
34,782	19.0%	+3,225
140,518	76.6%	+5,245
8,082	4.4%	+5,534
7,798		
168	—	—
115		
148,600	81.0%	+10,779
183,383	100.0%	+14,005

< Breakdown >

■ Current Asset : +7,426

- Cash, deposits (-365)
- Notes and accounts receivable (+2,884)
- Mk securities (-98)
- Inventory (+4,230)

■ Fixed Assets : +6,578

- Tangible Assets (-1,467)
- Intangible Assets (-14)
- Investments (+8,060)

■ Current Liabi: -628

- Notes Payable (+203)
- Other (-831)

■ Non-Current Liabilities : +3,854

Financial summary (Consolidated)

(¥ million)	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015 (forecast)
Sales (Exports)	104,069 (2,784)	103,232 (2,015)	107,031 (2,400)	111,400 (1,849)	113,121 (1,032)	120,200 (1,000)
Cost of Sales (cost of Sales Ratio) (%)	37,554 (36.1%)	36,926 (35.8%)	40,133 (37.5%)	43,047 (38.6%)	46,598 (41.2%)	—
SG&A Ratio to Sales (%)	50,071 (48.1%)	51,842 (50.2%)	48,949 (45.7%)	50,744 (45.6%)	51,785 (45.8%)	—
R&D Expenses Ratio to Sales (%)	12,495 (12.0%)	13,964 (13.5%)	11,059 (10.3%)	11,359 (10.2%)	13,514 (11.9%)	13,400 (11.1%)
Operating Income Ratio to Sales (%)	16,443 (15.8%)	14,464 (14.0%)	17,948 (16.8%)	17,607 (15.8%)	14,737 (13.0%)	16,000 (13.3%)
Ordinary Income Ratio to Sales (%)	17,110 (16.4%)	15,275 (14.8%)	18,676 (17.4%)	18,281 (16.4%)	15,490 (13.7%)	16,300 (13.6%)
Net Income Ratio to Sales (%)	10,927 (10.5%)	9,231 (8.9%)	12,422 (11.6%)	12,025 (10.8%)	12,064 (10.7%)	11,500 (9.6%)
EPS (¥)	146.21	123.54	166.25	160.95	161.63	155.51
Capital	700	700	700	700	700	—
Assets	147,234	145,673	154,968	169,378	183,383	—
shareholder's equity	112,076	117,931	126,985	135,273	140,518	—
Total Equity	111,706	118,201	129,099	137,821	148,600	—
BPS (¥)	1,494.83	1,581.94	1,727.86	1,844.61	2,009.45	—
ROE (%)	10.1%	8.0%	10.0%	9.0%	8.4%	—
Equity Ratio (%)	75.9%	81.1%	83.3%	81.4%	81.0%	—
Employees	2,294	2,297	2,444	2,452	2,445	—
Capital Expenditure	1,668	1,952	6,576	6,500	2,655	8,700
Depreciation Expense	2,458	2,363	2,738	3,153	3,053	3,800

Consolidated Financial Results and full year forecast



(Units: ¥ million)

	FY2013	FY2014	FY2015 (forecast)	Year on year	
				change	change (%)
Sales	111,400	113,121	120,200	+7,079	+6.3
■ Ethical Drugs business	109,678	111,771	118,600	+6,829	+6.1
◆ Sales of new Ethical Drugs	93,518	92,111	95,700	+3,589	+3.9
○ Japan	91,668	91,079	94,700	+3,621	+4.0
○ Overseas	1,849	1,032	1,000	-32	-3.1
◆ Generic Drugs	11,987	15,477	18,200	+2,723	+17.6
◆ Over-the-counter Drugs and Others	4,172	4,183	4,500	+317	+7.6
■ Consumer Healthcare Business	1,721	1,349	1,600	+251	+18.5
Operating Income	17,607	14,737	16,000	+1,263	+8.6
Ordinary Income	18,281	15,490	16,300	+810	+5.2
Net Income	12,025	12,064	11,500	-564	-4.7

P&L summary : KYORIN pharmaceutical (Non-consolidated)-(1)



(Units: ¥ million)

	FY2013		FY2014			
	Actual	% Sales	Actual	% Sales	% Change	Change
Sales	97,662	100.0%	98,452	100.0%	+0.8%	+790
■ Ethical Drugs business	97,662	100.0%	98,452	100.0%	+0.8%	+790
◆ Sales of new Ethical Drugs	89,846	92.0%	88,852	90.2%	-1.1%	-994
○ Japan	88,196	90.3%	88,012	89.4%	-0.2%	-184
○ Overseas	1,650	1.7%	840	0.9%	-49.1%	-810
◆ Generic Drugs	4,821	4.9%	6,404	6.5%	+32.8%	+1,583
◆ Over-the-counter Drugs and Others	2,994	3.1%	3,195	3.2%	+6.7%	+201

< Breakdown >

■ Sales	¥ 98,452	(+¥790)
● Ethical drug sales in Japan	¥88,012	(- ¥184)
	<u>FY13</u>	<u>FY14</u> (¥:billion)
• Kipres	40.2 ⇒	41.2 (+1.0)
• Mucodine	18.4 ⇒	14.0 (-4.4)
• Pentasa	18.6 ⇒	17.2 (-1.4)
• Uritos	8.1 ⇒	7.3 (-0.8)
• Flutiform	0.6 ⇒	3.6 (+3.0)
● Ethical drug sales overseas	¥840	(- ¥810)
• Gatifloxacin	1.5 ⇒	0.6 (-0.9)
● Generic Drugs	¥ 6,404	(+¥1,583)
	* increase of Kyorin Rimedio product sales	
● Over-the-counter Drugs and Others	¥3,195	(+ ¥201)
• Milton	2.1 ⇒	2.0 (-0.1)
• Rubysta	0.2 ⇒	0.5 (+0.3)

P&L summary : KYORIN pharmaceutical (Non-consolidated)-(2)



(Units: ¥ million)

	FY2013		FY2014			
	Actual	% Sales	Actual	% Sales	% Change	Change
Sales	97,662	100.0%	98,452	100.0%	+0.8%	+790
Cost of Sales	35,119	36.0%	38,951	39.6%	+10.9%	+3,832
Gross Profit	62,543	64.0%	59,501	60.4%	-4.9%	-3,042
SG&A (R&D Expenses)	47,175 (11,064)	48.3% (11.3%)	47,349 (12,843)	48.1% (13.0%)	+0.4% +16.1%	+174 +1,779
Operating Income	15,368	15.7%	12,151	12.3%	-20.9%	-3,217
Non-Operating Income	909	0.9%	964	1.0%	+6.1%	+55
Non-operating Expenses	46	0.0%	0	0.0%	-99.2%	-46
Ordinary Income	16,230	16.6%	13,115	13.3%	-19.2%	-3,115
Extraordinary Profits	235	0.2%	4,505	4.6%	+1810.4%	+4,270
Extraordinary Losses	52	0.1%	2,405	2.4%	+4521.7%	+2,353
Income before Income taxes	16,414	16.8%	15,215	15.5%	-7.3%	-1,199
Corporate, inhabitants and enterprise taxes	4,496	4.6%	3,998	4.1%	-11.1%	-498
Tax adjustments	1,094	1.1%	804	0.8%	-26.5%	-290
Net Income	10,823	11.1%	10,412	10.6%	-3.8%	-411

< Breakdown >

- ◆ Cost of Sales Ratio : +3.6percentage points
(36.0%→39.6%)
 - ・Drug price revisions (in the 6%range for KYORIN Pharmaceutical).
 - ・Product sales mix (increase of generic drugs sales)
- ◆ R&D Ratio : : +1.7 percentage points
(11.3%→13.0%)
 - * ¥11.1bln→¥12.8bln (+¥1.7bln)
 - ・ upfront payment of KRP-114V, progress of pipeline
- ◆ SG&A (exclude R&D) Expenses :
-2.0 percentage Points (37.0%→35.0%)
- Operating Income **12,151 (-3,217)**
- * Operating Income margin decreased 3.4percentage points to 12.3%
- Net Income **10,412 (-411)**

BS Summary: KYORIN Pharmaceutical (Non-consolidated)

(Units: ¥ million)

	FY2013	
	Actual	% total
Current Assets	92,209	70.4%
Cash, deposits	15,098	
Accounts receivable	40,133	
Mk securities	14,302	—
Inventory	17,969	
Other	4,705	
Fixed Assets	38,788	29.6%
Tangible assets	13,992	
Intangible assets	385	—
Investments	24,410	
Total Assets	130,997	100.0%

FY2013		
Actual	% total	change
97,822	68.4%	+5,613
14,587		
43,220		
12,804	—	—
21,763		
5,447		
45,145	31.6%	+6,357
12,324		
376	—	—
32,444		
142,967	100.0%	+11,970

Current Liabilities	20,446	15.6%
Notes Payable	7,473	—
Other	12,973	
Non-Current Liabilities	944	0.7%
Total Liabilities	21,391	16.3%
Owner's Equity	106,211	81.1%
Valuation and translation adjustments	3,394	2.6%
Total Equity	109,606	83.7%
Total Liabilities and Equity	130,997	100.0%

20,958	14.7%	+512
8,323	—	—
12,635		
3,762	2.6%	+2,818
24,720	17.3%	+3,329
110,534	77.3%	+4,323
7,712	5.4%	+4,318
118,246	82.7%	+8,640
142,967	100.0%	+11,970

< Breakdown >

■ Current Assets : +5,613

- Cash, deposits (-511)
- Accounts receivable (+3,087)
- Mk securities (-1,498)
- Inventory (+3,794)

■ Fixed Assets +6,357

- Tangible Assets (-1,668)
- Intangible Assets (-9)
- Investments (+8,034)

■ ■ Current Liabilities : +512

- Notes Payable (+850)
- Other (-338)

■ Non-Current Liabilities : +2,818

Financial Summary: KYORIN Pharmaceutical (Non-consolidated)

(¥ million)	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015 (forecast)
Sales (Exports)	92,531 (2,642)	93,697 (1,904)	95,894 (2,277)	97,662 (1,650)	98,452 (840)	105,300 (700)
Cost of Sales (cost of sales ratio) %	31,227 (33.7%)	32,046 (34.2%)	33,868 (35.3%)	35,119 (36.0%)	38,951 (39.6%)	—
SG&A Ratio to Sales (%)	45,658 (49.3%)	47,679 (50.9%)	44,898 (46.8%)	47,175 (48.3%)	47,349 (48.1%)	—
R&D Expenses Ratio to Sales (%)	11,867 (12.8%)	13,472 (14.4%)	10,733 (11.2%)	11,064 (11.3%)	12,843 (13.0%)	12,700 (12.1%)
Operating Income Ratio to Sales (%)	15,645 (16.9%)	13,971 (14.9%)	17,127 (17.9%)	15,368 (15.7%)	12,151 (12.3%)	13,300 (12.6%)
Ordinary Income Ratio to Sales (%)	16,729 (18.1%)	15,126 (16.1%)	18,209 (19.0%)	16,230 (16.6%)	13,115 (13.3%)	13,800 (13.1%)
Net Income Ratio to Sales (%)	10,732 (11.6%)	9,274 (9.9%)	11,931 (12.4%)	10,823 (11.1%)	10,412 (10.6%)	10,000 (9.5%)
EPS (¥)	144.51	124.88	160.66	145.74	140.20	—
Capital	4,317	4,317	4,317	4,317	4,317	—
Assets	122,661	121,985	121,881	130,997	142,967	—
shareholder's equity	95,719	101,652	100,586	106,211	110,534	—
Total Equity	95,573	102,177	102,844	109,606	118,246	—
BPS (¥)	1,286.87	1,375.79	1,384.77	1,475.82	1,592.16	—
ROE (%)	11.2%	9.4%	11.6%	10.2%	9.1%	—
Equity Ratio (%)	77.9%	83.8%	84.4%	83.7%	82.7%	—
Employees	1,804	1,798	1,797	1,780	1,771	—
Capital Expenditure	1,019	1,425	1,507	4,763	1,125	6,100
Depreciation Expense	1,968	1,790	1,743	1,743	1,667	2,200